FDA ap­proves Basilea’s an­tibi­ot­ic for se­vere bac­te­r­i­al in­fec­tions

The FDA on Wednes­day ap­proved Basilea’s an­tibi­ot­ic Zevtera to treat three con­di­tions: staph in­fec­tions, acute bac­te­r­i­al skin and skin struc­ture in­fec­tions, and com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia.

For com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia, the ap­proval in­cludes adults and pe­di­atric pa­tients old­er than 3 months.

The ap­pli­ca­tion for Zevtera, which is al­so known as cefto­bip­ro­le, was de­layed af­ter the com­pa­ny an­nounced it would push back its NDA plans last year due to man­u­fac­tur­ing is­sues. At that time, Basilea said the de­lay wasn’t re­lat­ed to the man­u­fac­tur­ing process or to the qual­i­ty or safe­ty of cefto­bip­ro­le. It in­stead cit­ed a need to up­date the “qual­i­ty sys­tem” of the con­tract man­u­fac­tur­ing or­ga­ni­za­tion dur­ing prepa­ra­tions for FDA in­spec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER